NCT03845075View on ClinicalTrials.gov

48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

October 16, 2020

Study Completion Date

October 16, 2020

Conditions
Hypothalamic Injury-induced Obesity (HIO)
Interventions
DRUG

Tesofensine/Metoprolol

During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)

DRUG

Placebo

During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol

Trial Locations (1)

210

Rigshospitalet, Copenhagen

Sponsors

Lead Sponsor

Saniona
All Listed Sponsors
lead

Saniona

INDUSTRY

NCT03845075 - 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO) | Biotech Hunter | Biotech Hunter